reported the USP8 silencing as a novel target to overcome gefitinib-mediated resistance in lung cancer, where gefitinib is a potent inhibitor of EGF receptor tyrosine kinase (EGFR-TKIs) (16). This evidence concerns the gene EGFR and lung carcinoma.